Between 2008 and 2019, around 50.9 percent of cardiovascular novel drugs in phase III continued to a New Drug Application (NDA) or a Biologic License Application (BLA). In total, only some six percent of cardiovascular novel drugs received approvals. This statistic illustrates the success rate of critical development in novel cardiovascular disease drugs in the United States from 2008 to 2019.
Success rate of novel cardiovascular disease drugs by development phase in the United States in 2008-2019
Profit from the additional features of your individual account
Currently, you are using a shared account. To use individual functions (e.g., mark statistics as favourites, set
statistic alerts) please log in with your personal account.
If you are an admin, please authenticate by logging in again.
Learn more about how Statista can support your business.
Biotechnology Innovation Organization. (June 30, 2020). Success rate of novel cardiovascular disease drugs by development phase in the United States in 2008-2019 [Graph]. In Statista. Retrieved November 21, 2024, from https://www.statista.com/statistics/1186648/us-clinical-development-success-rate-novel-cardiovascular-drugs/
Biotechnology Innovation Organization. "Success rate of novel cardiovascular disease drugs by development phase in the United States in 2008-2019." Chart. June 30, 2020. Statista. Accessed November 21, 2024. https://www.statista.com/statistics/1186648/us-clinical-development-success-rate-novel-cardiovascular-drugs/
Biotechnology Innovation Organization. (2020). Success rate of novel cardiovascular disease drugs by development phase in the United States in 2008-2019. Statista. Statista Inc.. Accessed: November 21, 2024. https://www.statista.com/statistics/1186648/us-clinical-development-success-rate-novel-cardiovascular-drugs/
Biotechnology Innovation Organization. "Success Rate of Novel Cardiovascular Disease Drugs by Development Phase in The United States in 2008-2019." Statista, Statista Inc., 30 Jun 2020, https://www.statista.com/statistics/1186648/us-clinical-development-success-rate-novel-cardiovascular-drugs/
Biotechnology Innovation Organization, Success rate of novel cardiovascular disease drugs by development phase in the United States in 2008-2019 Statista, https://www.statista.com/statistics/1186648/us-clinical-development-success-rate-novel-cardiovascular-drugs/ (last visited November 21, 2024)
Success rate of novel cardiovascular disease drugs by development phase in the United States in 2008-2019 [Graph], Biotechnology Innovation Organization, June 30, 2020. [Online]. Available: https://www.statista.com/statistics/1186648/us-clinical-development-success-rate-novel-cardiovascular-drugs/
